Severe hypoglycaemia

1 paper

Human trial1

Latest

5 in 12 months

Diabetologia3 h

HRS-7535 improved blood-sugar control in type 2 diabetes

A blood-sugar measure fell 16 and 20 mmol/mol with 30 mg and 60 mg daily, versus 4 mmol/mol with placebo over 16 weeks.A blood-sugar measure fell 16 and 20 mmol/mol with 30 mg and 60 mg daily, versus 4 mmol/mol with placebo over 16 weeks.

Randomised trial in 155 peopleType 2 diabetes

Lancet1 Oct

Orforglipron matches insulin glargine on cardiovascular safety

Over a median two years, major adverse cardiovascular events occurred in 4.2% of orforglipron participants compared with 5.0% of insulin glargine controls.Over a median two years, major adverse cardiovascular events occurred in 4.2% of orforglipron participants compared with 5.0% of insulin glargine controls.

Randomised trial in 2,749 peopleOrforglipron

The Lancet Diabetes & Endocrinology17 Aug

Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial

Randomised trial in 401 peopleOrforglipron

The Lancet Diabetes & Endocrinology13 Aug

Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial

Randomised trial in 485 peopleType 2 diabetes

Diabetes, Obesity & Metabolism7 Jul

Real-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers

Cohort study in peopleTirzepatide

The Lancet Diabetes & Endocrinology20 Aug

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

Meta-analysis of randomised trialsGLP-1 receptor agonists

Lancet27 Jun

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Randomised trial in 478 peopleGLP-1 receptor agonists

The Lancet Diabetes & Endocrinology14 Aug

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Meta-analysis of randomised trialsGLP-1 receptor agonists

Lancet4 Oct

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Randomised trial in 316 peopleGLP-1 receptor agonists